In this podcast, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talks with Prof. James Catto (GB) about the THOR-2 cohort 1 study: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients with high-risk non-muscle-invasive bladder cancer (NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received prior bacillus calmette-guérin (BCG) treatment.
Prof. Catto shares details on the rationale and design of the THOR-2 cohort 1 study, the results he presented at ESMO 2023, and some important take-home messages.
For more details on this study, you can read this abstract on the UROONCO Bladder Cancer educational platform.
In this podcast, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talks with Prof. James Catto (GB) about the THOR-2 cohort 1 study: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients with high-risk non-muscle-invasive bladder cancer (NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received prior bacillus calmette-guérin (BCG) treatment.
Prof. Catto shares details on the rationale and design of the THOR-2 cohort 1 study, the results he presented at ESMO 2023, and some important take-home messages.
For more details on this study, you can read this abstract on the UROONCO Bladder Cancer educational platform.